Hoffmann La Roche Company Profile
✉ Email this page to a colleague
What is the competitive landscape for HOFFMANN LA ROCHE, and when can generic versions of HOFFMANN LA ROCHE drugs launch?
HOFFMANN LA ROCHE has ten approved drugs.
There are six US patents protecting HOFFMANN LA ROCHE drugs.
There are one hundred and eighty patent family members on HOFFMANN LA ROCHE drugs in forty-six countries and twenty-three supplementary protection certificates in seventeen countries.
Summary for Hoffmann La Roche
International Patents: | 180 |
US Patents: | 6 |
Tradenames: | 9 |
Ingredients: | 8 |
NDAs: | 10 |
Drugs and US Patents for Hoffmann La Roche
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hoffmann La Roche | ZELBORAF | vemurafenib | TABLET;ORAL | 202429-001 | Aug 17, 2011 | RX | Yes | Yes | 8,741,920 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Hoffmann La Roche | ACCUTANE | isotretinoin | CAPSULE;ORAL | 018662-003 | May 7, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Hoffmann La Roche | ZELBORAF | vemurafenib | TABLET;ORAL | 202429-001 | Aug 17, 2011 | RX | Yes | Yes | 7,504,509 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Hoffmann La Roche | ROCEPHIN | ceftriaxone sodium | INJECTABLE;INJECTION | 063239-003 | Aug 13, 1993 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Hoffmann La Roche | ZELBORAF | vemurafenib | TABLET;ORAL | 202429-001 | Aug 17, 2011 | RX | Yes | Yes | 9,447,089 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Hoffmann La Roche | ACCUTANE | isotretinoin | CAPSULE;ORAL | 018662-004 | Mar 28, 1983 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Hoffmann La Roche | BONIVA | ibandronate sodium | TABLET;ORAL | 021455-002 | Mar 24, 2005 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Hoffmann La Roche
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Hoffmann La Roche | ACCUTANE | isotretinoin | CAPSULE;ORAL | 018662-004 | Mar 28, 1983 | 4,464,394*PED | ⤷ Try a Trial |
Hoffmann La Roche | ACCUTANE | isotretinoin | CAPSULE;ORAL | 018662-002 | May 7, 1982 | 4,464,394*PED | ⤷ Try a Trial |
Hoffmann La Roche | BONIVA | ibandronate sodium | TABLET;ORAL | 021455-002 | Mar 24, 2005 | 7,192,938 | ⤷ Try a Trial |
Hoffmann La Roche | ACCUTANE | isotretinoin | CAPSULE;ORAL | 018662-002 | May 7, 1982 | 4,200,647 | ⤷ Try a Trial |
Hoffmann La Roche | ACCUTANE | isotretinoin | CAPSULE;ORAL | 018662-003 | May 7, 1982 | 4,464,394*PED | ⤷ Try a Trial |
Hoffmann La Roche | FORTOVASE | saquinavir | CAPSULE;ORAL | 020828-001 | Nov 7, 1997 | 6,008,228*PED | ⤷ Try a Trial |
Hoffmann La Roche | FORTOVASE | saquinavir | CAPSULE;ORAL | 020828-001 | Nov 7, 1997 | 6,352,717*PED | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for HOFFMANN LA ROCHE drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Injection | 1 mg/mL, 3 mL Vial | ➤ Subscribe | 2007-08-31 |
➤ Subscribe | Tablets | 2.5 mg and 150 mg | ➤ Subscribe | 2007-05-16 |
International Patents for Hoffmann La Roche Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
South Africa | 200709919 | ⤷ Try a Trial |
Germany | 122012000043 | ⤷ Try a Trial |
Malaysia | 160737 | ⤷ Try a Trial |
Canada | 2608733 | ⤷ Try a Trial |
South Africa | 201202026 | ⤷ Try a Trial |
Taiwan | I432193 | ⤷ Try a Trial |
Japan | 5934742 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Hoffmann La Roche Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0432695 | 96C0044 | Belgium | ⤷ Try a Trial | PRODUCT NAME: SAQUINAVIR; REGISTRATION NO/DATE: EU/1/96/026/001 19961004 |
1893612 | 12C0040 | France | ⤷ Try a Trial | PRODUCT NAME: VEMURAFENIB, EVENTUELLEMENT SOUS LA FORME D'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/12/751/001 20120221 |
0034432 | 96C0048 | Belgium | ⤷ Try a Trial | PRODUCT NAME: SAQUINAVIR; REGISTRATION NO/DATE: EU/1/96/026/001 19961004 |
1893612 | CA 2012 00028 | Denmark | ⤷ Try a Trial | |
1893612 | C20120016 00059 | Estonia | ⤷ Try a Trial | PRODUCT NAME: ZELBORAF - VEMURAFENIIB;REG NO/DATE: C(2012)1180 FINAL 17.02.2012 |
1893612 | 28/2012 | Austria | ⤷ Try a Trial | PRODUCT NAME: VEMURAFENIB UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; REGISTRATION NO/DATE: EU/1/12/751/001 (MITTEILUNG) 20120221 |
1893612 | 2012/025 | Ireland | ⤷ Try a Trial | PRODUCT NAME: VEMURAFENIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/12/751/001 20120217 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.